INFOHaem™ MSS Can12™ FAQ

What is the Predisposition Test for Cancers (Can12)?

The Predisposition Test for Cancers evaluates an individual’s lifetime risk of developing 12 prevalent types of cancers. It uses a two-pronged approach, molecular and clinical examinations. Molecular examination involves the genotyping of one’s DNA, in search of a panel of 768 SNPs inherited from one’s parents that predispose an individual to either increased or decreased risk of developing cancers. Clinical examination associates one’s lifestyle choices, family history and medical history to cancer risk. The combined clinico-molecular analysis thus provides a more thorough and comprehensive cancer risk assessment than each of the two examinations alone. The 12 types of cancers are:

  • Breast cancer
  • Cervical cancer
  • Colorectal cancer
  • Gastric cancer
  • Leukemia
  • Liver cancer
  • Lung cancer
  • Nasopharyngeal cancer
  • Oral cancer
  • Ovarian cancer
  • Prostate cancer
  • Thyroid cancer


What is the procedure involved?

A small sample of buccal cells or blood (about 5ml) will be drawn and clinical information will be collected. The procedure is minimally-invasive. DNA will be extracted from the blood sample and subjected to microarray technology based SNP genotyping. Clinical information will be examined by our panel of physicians.


Who should take this test?

Any individual who has never been diagnosed with any type of cancers will benefit from this test. An individual who has suffered cancer should also consider ordering the test for oneself, his/her offspring and blood relatives for comparative study, in order to ascertain if the same cancer-causing genetic markers have been passed on or shared among the family members.


Are your clients required to take the same test again in the future?

The molecular test result represents one’s genetic profile at that time of testing. The probability of your DNA getting mutations at the exact locations of risk-associated SNPs is low within a short span of time. However, we upgrade our panel of SNPs regularly, in order to keep up to date with the latest scientific discovery on cancer-genotype association. Every upgrade is a step forward for the fine-tuning of cancer risk assessment and towards fulfilling the goal of personalized medicine. You will be informed of the upgrades when available.


Has the Test Been Validated?

The validation studies involved the collaboration between INFOVALLEY® and various hospitals and medical centres, namely Hospital Wijaya, Hospital Sri Kota, Radiotherapy and Oncology Department of Hospital Sultan Ismail Johor, Obstetrics and Gynecology Department and Oncology Department of Hospital Kuala Lumpur, Obstetrics and Gynecology Department,  Oral Surgery Specialist Clinic and Ear, Nose and Throat (ENT) Department of Hospital Putrajaya.


The association of the 768 SNPs with the 12 cancer types  and the risk classification according to the comparative study of the genomic profile of cancer patients with that of healthy individuals has been independently validated at INFOVALLEY molecular research laboratory. Illumina microarray platform (on custom design BeadChip) was employed in the research. Each polymorphism and mutation will be tested for Hardy-Weinberg equilibrium, whereby the significance of the polymorphisms and mutations was tested by Leave-one-out (LOO) cross-validation. The k-CGS and k-ACS methods were performed for the identification of risk-associated and protective genetic markers. The study is focus on predictive power of not individual but a collection of genetic markers.


Is there any publication / patent on the validation study?


Coming Soon!


More validation studies will be published in the internationally recognized scientific journals once the company completed its product patent application exercise. INFOVALLEY® holds the IP right towards INFOHaem™ Can12. Patent/copyright infringement and trademark violation is an offense according to The Malaysia Patent Act 1983 and the Patent Regulations 1986.